argenx SE
Develops and commercializes antibody-based therapies for severe autoimmune diseases.
1AE | BR
Overview
Corporate Details
- ISIN(s):
- NL0010832176 (+1 more)
- LEI:
- 7245009C5FZE6G9ODQ71
- Country:
- Netherlands
- Address:
- Laarderhoogtweg 25, 1101EB Amsterdam
- Website:
- https://www.argenx.com/?allow=1
- Sector:
- Manufacturing
Description
argenx SE is a global immunology company that develops and commercializes antibody-based therapies for severe autoimmune diseases. Its lead product, efgartigimod, is a neonatal Fc receptor (FcRn) antagonist designed to reduce pathogenic Immunoglobulin G (IgG) antibodies. Efgartigimod is marketed as VYVGART and VYVGART Hytrulo for approved indications including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company is investigating efgartigimod for several other autoimmune conditions. Its pipeline also includes other first-in-class candidates, such as empasiprubart, a C2 inhibitor for IgM-driven autoimmune diseases. argenx operates an antibody innovation platform, collaborating with academic partners to translate immunology research into therapeutic candidates.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-06-23 07:37 |
argenx Announces European Commission Approval of VYVGART Subcutaneous Injection…
|
English | 57.6 KB | ||
| 2025-06-11 08:15 |
argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase…
|
English | 154.7 KB | ||
| 2025-03-20 07:09 |
argenx SE, Jaarlijkse financiële verslaggeving
|
English | 33.5 MB | ||
| 2025-03-07 07:41 |
argenx Highlights FcRn Leadership with Long-term Data and Transformational Pati…
|
English | 180.7 KB | ||
| 2025-01-06 07:42 |
argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference
|
English | 21.5 KB | ||
| 2024-12-27 08:43 |
argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc)…
|
English | 63.3 KB | ||
| 2024-11-26 07:38 |
argenx to Present at Upcoming Investor Conferences
|
English | 26.2 KB | ||
| 2024-11-11 13:45 |
argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammator…
|
English | 59.1 KB | ||
| 2024-11-05 07:35 |
argenx to Participate at Upcoming Investor Conferences
|
English | 25.1 KB | ||
| 2024-10-31 07:40 |
argenx Reports Third Quarter 2024 Financial Results and Provides Business Update
|
English | 154.5 KB | ||
| 2024-10-24 07:40 |
argenx to Report Third Quarter 2024 Financial Results and Business Update on Oc…
|
English | 22.7 KB | ||
| 2024-09-19 09:48 |
argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Da…
|
English | 108.5 KB | ||
| 2024-08-28 08:38 |
argenx to Present at Upcoming Investor Conferences
|
English | 25.6 KB | ||
| 2024-07-25 07:37 |
argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Bus…
|
English | 143.7 KB | ||
| 2024-07-18 07:38 |
argenx to Report Half Year 2024 Financial Results and Second Quarter Business U…
|
English | 20.4 KB |
Automate Your Workflow. Get a real-time feed of all argenx SE filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for argenx SE
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for argenx SE via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
